First-generation antipsychotics explained

What first-generation antipsychotics are

The first-generation antipsychotics are the original antipsychotic medications. The name comes from the timeline. They were the first group to arrive, starting with chlorpromazine in the early 1950s, and they were what psychiatry had for schizophrenia and other psychotic illnesses until the atypicals joined them in the 1990s.

They're sometimes called typical antipsychotics or classical antipsychotics or neuroleptics. Those names all refer to the same group. The medications in this class differ in potency, meaning how many milligrams it takes to get the same antipsychotic effect. High-potency first-gens (haloperidol, fluphenazine) work at doses of a few milligrams. Low-potency first-gens (chlorpromazine, thioridazine) require hundreds of milligrams to reach the same effect. Potency isn't strength in the everyday sense. It changes the side-effect profile more than the effectiveness.

The first-generation antipsychotics covered here include haloperidol, chlorpromazine, fluphenazine, perphenazine, trifluoperazine, thiothixene, loxapine, molindone, pimozide, thioridazine, and droperidol.

How they work

Nerve cells in the brain pass messages using chemical messengers. Dopamine is one of them. Receptors are the docking points cells use to receive those messages, and there are several types. The dopamine D2 receptor is the one most relevant to antipsychotic activity.

First-generation antipsychotics block D2 receptors. That's the defining feature of the class, and it's what quiets the positive symptoms of psychosis (hallucinations, delusions, disorganized thinking). All antipsychotics do this to some degree. What distinguishes the first-gens is that D2 blocking is essentially all they do at usual doses. They don't have the serotonin receptor activity that softens the D2 effect in the atypicals.

Dopamine has jobs in more than one part of the brain. Blocking D2 in the mesolimbic pathway is what eases psychosis. Blocking D2 in the nigrostriatal pathway is what causes movement side effects (parkinsonism, akathisia, dystonia, and over time tardive dyskinesia). Blocking D2 in the tuberoinfundibular pathway raises prolactin. Blocking D2 in the mesocortical pathway may worsen negative symptoms and cognitive symptoms. First-gens hit all these pathways together, which is why they treat psychosis and cause movement side effects at the same time.

Low-potency first-gens (chlorpromazine, thioridazine) also block muscarinic acetylcholine, histamine H1, and alpha-1 adrenergic receptors. That's why they're more sedating, more anticholinergic, and more likely to cause orthostatic hypotension than the high-potency ones, and why they cause less movement side effects at a given clinical dose. High-potency first-gens (haloperidol, fluphenazine) mostly hit D2, so they're less sedating and less anticholinergic but more likely to cause movement problems.

How the class developed

Chlorpromazine, the first antipsychotic, came out of a French search for better antihistamines and surgical anesthesia adjuncts in the late 1940s. Henri Laborit, a French surgeon, noticed that chlorpromazine made surgical patients calm and detached without simply sedating them. Two French psychiatrists, Jean Delay and Pierre Deniker, tried it in patients with agitation and psychosis in 1952 and reported dramatic results. It reached hospitals in the U.S. by 1954, and the way psychiatric care worked changed. For the first time there was a medication that reliably reduced hallucinations, delusions, and severe agitation. Many patients who had been living in long-stay psychiatric hospitals could leave.

Other first-generation antipsychotics followed through the 1950s and 1960s. Haloperidol, developed in Belgium, became one of the most widely used. Long-acting injectable forms of haloperidol and fluphenazine were developed for people who couldn't reliably take a daily pill. These are still used today.

The problems with the first-gens came into focus over the following decades. Movement side effects were common. Tardive dyskinesia, a movement disorder that develops over long-term use, became a concern in the 1970s and 1980s. The atypical antipsychotics that arrived from the 1990s onward were developed to reduce these problems. They mostly did, though they brought their own set of concerns around weight, blood sugar, and cholesterol.

One landmark study is worth mentioning. The CATIE trial, published in 2005, was a large NIH-funded head-to-head comparison of a first-generation antipsychotic (perphenazine) against several atypicals in people with chronic schizophrenia. Perphenazine did roughly as well as most of the atypicals, and it did it at lower cost. That result reset some assumptions about first-gens being uniformly worse.

What they treat

First-generation antipsychotics are used for several conditions.

• Schizophrenia. Haloperidol and fluphenazine are the ones most often used today for schizophrenia, especially in inpatient settings and for people already on a first-gen who are doing well.
• Acute agitation. Haloperidol and droperidol given by injection are workhorses in emergency rooms and hospital settings for acute agitation, whether from psychosis, mania, or other causes.
• Tourette's syndrome. Haloperidol and pimozide are FDA-approved for tics that are severe enough to require medication.
• Long-acting maintenance treatment. Haloperidol decanoate and fluphenazine decanoate are long-acting injectable forms given every two to four weeks. They're used for people with schizophrenia when reliable daily dosing is hard.
• Nausea and vomiting. Some first-gens (chlorpromazine, prochlorperazine) are used for severe nausea, though prochlorperazine isn't typically included in the psychiatric list.
• Intractable hiccups. Chlorpromazine is one of the classic treatments for hiccups that don't stop.

First-gens are less often used for bipolar disorder, depression augmentation, or autism-related irritability. Those roles have largely gone to the atypicals.

Individual medications in this class

• Haloperidol (Haldol). The most widely used first-gen. High-potency, meaning small milligram doses. Available as an oral tablet, an oral solution, a short-acting IM injection for acute agitation, and a long-acting depot injection (decanoate) for maintenance treatment.
• Chlorpromazine (Thorazine). The first antipsychotic. Low-potency, meaning larger doses. More sedating and more anticholinergic than the high-potency options. Still used occasionally, including for intractable hiccups.
• Fluphenazine (Prolixin). High-potency. Available as an oral form and as a long-acting depot injection (decanoate) similar to haloperidol.
• Perphenazine (Trilafon). Medium-potency. The first-gen that held up in the CATIE trial against several atypicals. Less commonly prescribed than it probably should be.
• Trifluoperazine (Stelazine). High-potency. Sometimes used for schizophrenia and, historically, for short-term treatment of generalized anxiety.
• Thiothixene (Navane). A thioxanthene-class first-gen. High-potency. Used less often today.
• Loxapine (Loxitane, Adasuve). Medium-potency. Available as an oral form and as an inhaled powder (Adasuve) approved for acute agitation in schizophrenia and bipolar disorder.
• Molindone (Moban). Medium-potency. Notable for having less associated weight gain than most first-gens, though supply has been intermittent.
• Pimozide (Orap). Used mainly for Tourette's syndrome. Has notable QT interval concerns and is metabolized by CYP3A4, which means significant drug interactions.
• Thioridazine (Mellaril). Low-potency. Now rarely used because of significant QT prolongation risk and reports of retinal damage at higher doses. Restricted to schizophrenia that hasn't responded to other options.
• Droperidol (Inapsine). Given by injection for acute agitation, mainly in emergency and perioperative settings. Carries a boxed warning about QT prolongation.

Common side effects across the class

The side effects most often seen with first-generation antipsychotics.

• Extrapyramidal side effects (EPS). This umbrella covers parkinsonism (stiffness, tremor, slowed movement), akathisia (a feeling of inner restlessness), and acute dystonic reactions (sudden muscle spasms of the neck, jaw, or eyes). These come from D2 blocking in the movement pathways and are more common with high-potency first-gens.
• Tardive dyskinesia. Repetitive involuntary movements, often of the face, mouth, or tongue, that can develop with long-term use. The risk rises the longer someone is on an antipsychotic, and first-gens carry a higher risk than atypicals.
• Sedation and drowsiness. Most prominent with low-potency first-gens (chlorpromazine, thioridazine).
• Raised prolactin. This can cause missed periods, breast tenderness, milk production not related to breastfeeding, and sexual side effects. Common across the class.
• Weight gain. Less pronounced than with many atypicals (olanzapine, clozapine, quetiapine), but still real.
• Dry mouth, constipation, blurry vision, urinary retention. Anticholinergic effects, more prominent with low-potency first-gens.
• Orthostatic hypotension (lightheadedness on standing). More common with low-potency first-gens.
• Sexual side effects.

Metabolic effects (weight, blood sugar, cholesterol) still occur with first-gens but are generally less severe than with olanzapine or clozapine. That's part of why perphenazine and haloperidol still have a place today for people at high metabolic risk.

Serious warnings across the class

The warnings that matter most.

• FDA boxed warning about increased risk of death in older adults with dementia-related psychosis. This warning applies to all antipsychotics, first-gen and atypical alike. Antipsychotics aren't approved for dementia-related psychosis, though they're sometimes used off-label for severe agitation.
• Neuroleptic malignant syndrome (NMS). A rare but potentially fatal reaction. Signs include high fever, severe muscle stiffness, confusion, and unstable heart rate and blood pressure. It's a medical emergency. NMS can happen with any antipsychotic but is a particular concern with high-potency first-gens.
• Tardive dyskinesia. The risk goes up the longer someone is on an antipsychotic. First-gens carry a higher long-term TD risk than atypicals. Any new involuntary movements should be reported early.
• QT prolongation. Several first-gens can prolong the QT interval on the ECG, including thioridazine, pimozide, droperidol, and haloperidol (especially IV). Baseline and follow-up ECGs may be checked.
• Acute dystonic reactions. Sudden, painful muscle spasms of the neck, jaw, tongue, or eyes. These come on within hours to days of starting a high-potency first-gen or after a dose increase. They're distressing but treatable, usually with intramuscular benztropine or diphenhydramine.
• Anticholinergic burden. Low-potency first-gens carry significant anticholinergic effects, which matter especially in older adults.
• Seizure threshold. First-gens can lower the seizure threshold.
• Hyperprolactinemia. Long-term high prolactin can affect bone density, sexual function, and menstruation.

What tips the choice within the class

The choice among first-gens depends on the situation.

Route and setting. For acute agitation in an emergency setting, haloperidol IM and droperidol IM are the workhorses. Inhaled loxapine is another option for acute agitation. For daily oral maintenance, haloperidol, perphenazine, and fluphenazine are the ones most commonly chosen. For long-acting injectable maintenance, haloperidol decanoate and fluphenazine decanoate are the classic options.

Potency and side-effect fit. High-potency first-gens (haloperidol, fluphenazine, trifluoperazine, thiothixene) have less sedation, less anticholinergic effect, and less orthostatic hypotension, but more movement side effects. Low-potency first-gens (chlorpromazine, thioridazine) are more sedating and more anticholinergic, but cause less parkinsonism at clinically equivalent doses.

Specific indications. Pimozide and haloperidol have specific evidence in Tourette's. Chlorpromazine remains one of the classic treatments for intractable hiccups. Loxapine's inhaled form is specific to acute agitation.

QT concerns. In people with heart disease, longer QT at baseline, or on other QT-prolonging medications, thioridazine, pimozide, and IV haloperidol are usually avoided or dosed with more monitoring.

Reliability of daily dosing. For someone whose treatment has been derailed by inconsistent daily medication, a long-acting injectable (haloperidol decanoate or fluphenazine decanoate) can be a good fit.

Monitoring on any first-gen usually includes AIMS (the Abnormal Involuntary Movement Scale, checked at least yearly), ECG when clinically indicated, prolactin when there are symptoms, and metabolic labs annually.

Common questions

Why would anyone choose a first-gen over a newer atypical? A few reasons. Cost is one, since many first-gens are inexpensive generics. Metabolic side effects are usually milder than with olanzapine, clozapine, or quetiapine, so a first-gen can be a better fit for someone at high risk of diabetes or weight gain. Some people simply do better on a specific first-gen than on any atypical they've tried. And CATIE, the largest head-to-head trial in schizophrenia, showed perphenazine holding up against several atypicals on how long people stayed on the medication.

What is tardive dyskinesia and how likely is it? Tardive dyskinesia (TD) is a movement disorder that can develop with long-term antipsychotic use. It involves repetitive, involuntary movements, often of the face, mouth, or tongue (lip smacking, tongue movements, grimacing), and it can involve the limbs or trunk. With first-generation antipsychotics, roughly 4% to 5% of adults develop TD per year of treatment, and the cumulative risk is higher over long-term use. The risk is higher in older adults. TD sometimes improves after the antipsychotic is stopped or reduced, but it can be permanent. Any new involuntary movements should be reported to the prescriber early.

Are first-gens still used for acute agitation? Yes. Haloperidol IM (often combined with lorazepam and sometimes diphenhydramine or benztropine) is one of the most used treatments for acute agitation in emergency departments and hospitals. Droperidol IM is used similarly. Inhaled loxapine is another option. For agitation not related to psychosis, benzodiazepines alone may be enough, but for agitation with psychosis or mania, haloperidol is a mainstay.

What is the difference between high-potency and low-potency first-gens? Potency refers to the milligram dose needed for the same clinical effect. High-potency first-gens (haloperidol, fluphenazine, trifluoperazine) work at small doses and mainly block D2 receptors. Low-potency first-gens (chlorpromazine, thioridazine) require larger doses and also block acetylcholine, histamine, and alpha-1 receptors. The trade-off: high-potency has more movement side effects but less sedation, while low-potency has less movement side effects but more sedation, anticholinergic effects, and orthostatic hypotension.

What monitoring is standard on a first-generation antipsychotic? AIMS (a movement disorder screen) at baseline and at least yearly. ECG at baseline and periodically if there's QT concern or the medication is one with more QT risk (thioridazine, pimozide, IV haloperidol). Prolactin if there are symptoms. Metabolic labs (weight, waist circumference, fasting glucose or HbA1c, lipid panel) annually, since some metabolic risk still applies. Symptoms of NMS (high fever, muscle stiffness, confusion) are what prescribers ask patients and families to watch for and report right away.

Sources

This guide draws on current prescribing information and public health references. It's reviewed for clinical accuracy and updated as guidance changes. This is educational and isn't medical advice.

1. U.S. Food and Drug Administration. Prescribing information.
2. MedlinePlus, U.S. National Library of Medicine.
3. National Institute of Mental Health. Mental health medications.
4. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia.
5. Lieberman JA, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia (CATIE). NEJM 2005.